Form 8-K - Current report:
SEC Accession No. 0001493152-24-043754
Filing Date
2024-11-06
Accepted
2024-11-06 08:00:26
Documents
16
Period of Report
2024-11-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 47458
2 ex4-1.htm EX-4.1 133626
3 ex10-1.htm EX-10.1 78290
4 ex10-2.htm EX-10.2 46390
  Complete submission text file 0001493152-24-043754.txt   541979

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE zvsa-20241105.xsd EX-101.SCH 3012
6 XBRL LABEL FILE zvsa-20241105_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE zvsa-20241105_pre.xml EX-101.PRE 24163
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3820
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 241429288
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)